- Home
- EVAX vs SONN Comparison
EVAX vs SONN Comparison
Compare EVAX & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- SONN
- Stock Information
- Founded
- EVAX 2008
- SONN N/A
- Country
- EVAX Denmark
- SONN United States
- Employees
- EVAX N/A
- SONN N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- EVAX Health Care
- SONN Health Care
- Exchange
- EVAX Nasdaq
- SONN Nasdaq
- Market Cap
- EVAX 17.8M
- SONN 21.4M
- IPO Year
- EVAX 2021
- SONN N/A
- Fundamental
- Price
- EVAX $2.95
- SONN $7.58
- Analyst Decision
- EVAX Strong Buy
- SONN Strong Buy
- Analyst Count
- EVAX 2
- SONN 1
- Target Price
- EVAX $10.00
- SONN $20.00
- AVG Volume (30 Days)
- EVAX 68.5K
- SONN 1.4M
- Earning Date
- EVAX 10-30-2025
- SONN 08-13-2025
- Dividend Yield
- EVAX N/A
- SONN N/A
- EPS Growth
- EVAX N/A
- SONN N/A
- EPS
- EVAX N/A
- SONN N/A
- Revenue
- EVAX $3,176,000.00
- SONN $1,000,000.00
- Revenue This Year
- EVAX N/A
- SONN $5,376.22
- Revenue Next Year
- EVAX $425.50
- SONN N/A
- P/E Ratio
- EVAX N/A
- SONN N/A
- Revenue Growth
- EVAX 1042.45
- SONN 1689.52
- 52 Week Low
- EVAX $1.20
- SONN $1.08
- 52 Week High
- EVAX $16.69
- SONN $19.30
- Technical
- Relative Strength Index (RSI)
- EVAX 52.92
- SONN 78.27
- Support Level
- EVAX $2.81
- SONN $2.71
- Resistance Level
- EVAX $3.04
- SONN $7.90
- Average True Range (ATR)
- EVAX 0.22
- SONN 0.90
- MACD
- EVAX -0.00
- SONN 0.48
- Stochastic Oscillator
- EVAX 69.35
- SONN 91.71
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.